Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:HEPA NASDAQ:LPCN NASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.23-2.6%$2.71$1.21▼$7.13$150.74M0.45314,459 shs319,295 shsHEPAHepion Pharmaceuticals$0.05-1.7%$0.05$0.03▼$0.10$607K1.5217,495 shs20,128 shsLPCNLipocine$2.33+1.7%$5.59$1.81▼$12.37$18.38M0.5525,153 shs94,792 shsSYBXSynlogic$0.65+8.9%$0.63$0.54▼$1.96$7.59M0.5274,584 shs4,032 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics-1.76%-3.88%-16.48%-24.66%+70.23%HEPAHepion Pharmaceuticals-15.58%-24.14%-3.45%-2.39%-82.15%LPCNLipocine0.00%+0.87%+13.66%-71.52%-32.66%SYBXSynlogic+7.27%+1.41%+9.08%+2.20%-44.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.23-2.6%$2.71$1.21▼$7.13$150.74M0.45314,459 shs319,295 shsHEPAHepion Pharmaceuticals$0.05-1.7%$0.05$0.03▼$0.10$607K1.5217,495 shs20,128 shsLPCNLipocine$2.33+1.7%$5.59$1.81▼$12.37$18.38M0.5525,153 shs94,792 shsSYBXSynlogic$0.65+8.9%$0.63$0.54▼$1.96$7.59M0.5274,584 shs4,032 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics-1.76%-3.88%-16.48%-24.66%+70.23%HEPAHepion Pharmaceuticals-15.58%-24.14%-3.45%-2.39%-82.15%LPCNLipocine0.00%+0.87%+13.66%-71.52%-32.66%SYBXSynlogic+7.27%+1.41%+9.08%+2.20%-44.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 2.00Hold$11.00393.27% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/ALPCNLipocine 2.33Hold$15.00543.78% UpsideSYBXSynlogic 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SYBX, LPCN, GALT, and HEPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/27/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ALPCNLipocine$1.98M9.45N/AN/A$2.61 per share0.89SYBXSynlogic$8K949.08N/AN/A$1.09 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$30.84M-$0.48N/AN/AN/AN/AN/A-214.23%5/21/2026 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%5/12/2026 (Estimated)LPCNLipocine-$9.63M-$1.69N/AN/AN/A-487.00%-59.30%-53.37%5/7/2026 (Estimated)SYBXSynlogic-$23.36M-$0.08N/AN/AN/AN/A-26.47%-18.00%5/6/2026 (Estimated)Latest SYBX, LPCN, GALT, and HEPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GALTGalectin Therapeutics-$0.06N/AN/AN/AN/AN/A5/12/2026Q1 2026HEPAHepion Pharmaceuticals-$200.00N/AN/AN/AN/AN/A5/7/2026Q1 2026LPCNLipocine-$0.51N/AN/AN/A$0.16 millionN/A3/30/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/10/2026Q4 2025LPCNLipocine-$0.60-$0.34+$0.26-$0.34$0.12 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A2.422.42HEPAHepion PharmaceuticalsN/A1.301.30LPCNLipocineN/A6.686.68SYBXSynlogicN/A2.652.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%HEPAHepion Pharmaceuticals17.24%LPCNLipocine9.11%SYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics52.60%HEPAHepion Pharmaceuticals0.06%LPCNLipocine6.35%SYBXSynlogic2.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics965.83 million31.20 millionOptionableHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataLPCNLipocine108.03 million7.52 millionNo DataSYBXSynlogic8011.70 million11.39 millionNo DataSYBX, LPCN, GALT, and HEPA HeadlinesRecent News About These CompaniesSynlogic's Strategic Crossroads: A Company in LimboFebruary 10, 2026 | aktiencheck.deASynlogic Challenges Nasdaq Delisting NoticeNovember 26, 2025 | tipranks.comWe Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business GrowthSeptember 18, 2025 | uk.finance.yahoo.comSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comPSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comMThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYBX, LPCN, GALT, and HEPA Company DescriptionsGalectin Therapeutics NASDAQ:GALT$2.23 -0.06 (-2.62%) As of 05/5/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Hepion Pharmaceuticals NASDAQ:HEPA$0.05 0.00 (-1.67%) As of 05/5/2026 02:37 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Lipocine NASDAQ:LPCN$2.33 +0.04 (+1.75%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$2.32 -0.01 (-0.39%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Synlogic NASDAQ:SYBX$0.65 +0.05 (+8.89%) As of 05/4/2026 03:59 PM EasternSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
